NEWS

"img

The Sermonix Blog

Sermonix Announces FDA Acceptance of IND Application; Will Begin Phase 2 Trial of Lasofoxifene for Targeted Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

Study, set to commence in early 2019, will evaluate activity of oral lasofoxifene versus IM fulvestrant for treatment of postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation COLUMBUS, Ohio, Dec. 10, 2018 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and [...]
Read more

Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium

Posters to be displayed at Dec. 4-8 conference address introduction of Phase 2 study of investigational drug lasofoxifene, its effect on breast cancer and lung and liver metastasis in an in vivo model, and oncologists’ perceptions of ESR1 mutations and biomarker testing. COLUMBUS, Ohio, Nov. 14, 2018 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately […]
Read more

Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer

Linical Accelovance Group will serve as research partner for study that compares lasofoxifene to fulvestrant. COLUMBUS, Ohio, Oct. 09, 2018 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced the launch of a Phase 2 trial for the treatment of [...]
Read more

Sermonix Pharmaceuticals Announces Recent Closure of $4.2 Million Seed Preferred Equity Bridge to Fund Operations, Prepare for Phase II Breast Cancer Study

Biotechnology company will globally develop and commercialize drug for treatment of advanced metastatic breast cancer. COLUMBUS, OH–(Marketwired – Oct 31, 2017) – Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced its recent completion of a $4.2 million [...]
Read more

Sermonix Pharmaceuticals Secures Worldwide Rights to Oral Lasofoxifene From Ligand Pharmaceuticals, Expanding From U.S., Japan

Accord allows Sermonix to globally develop and commercialize drug for treatment of advanced breast cancer COLUMBUS, OH–(Marketwired – Feb 28, 2017) – Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced it licensed worldwide rights to develop and [...]
Read more

Sermonix Pharmaceuticals Signs Exclusive Licensing Agreement to Further Explore Lasofoxifene For Breast Cancer Treatment

Women’s Oncology Pharmaceutical Company Also Raises More Than $2 Million in Preferred Seed Funding Round  COLUMBUS, OH, (December 7, 2016) – Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced that it signed a licensing agreement through which Sermonix will gain exclusive [...]
Read more

Sermonix Pharmaceuticals to Present Poster on Physician Perceptions of Menopausal Serms at San Antonio Breast Cancer Symposium

 COLUMBUS, OH (November 28, 2016) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that its poster on physician perceptions of estrogen agonist/antagonists in menopausal health has been accepted for presentation at the San Antonio Breast Cancer Symposium (SABC). The Dec. [...]
Read more

Sermonix Pharmaceuticals’ Exploratory Analysis on Orgasm Frequency With SERMs Is Named Featured Poster for 2016 North American Menopause Society Annual Meeting

Sermonix Also to Present Poster on Physicians’ Perceptions of SERMs in Menopausal Health COLUMBUS, OH–(Marketwired – Sep 26, 2016) – Sermonix Pharmaceuticals Inc., a specialty pharmaceutical company focused on late-stage women’s health products, today announced that its exploratory analysis on sexual activity and orgasm frequency in menopause will be one of three [...]
Read more

Sermonix Pharmaceuticals Convenes Breast Cancer Oncology Steering Committee to Explore Utility of Lasofoxifene

COLUMBUS, OH–(Marketwired – Aug 3, 2016) – Sermonix Pharmaceuticals LLC, a specialty pharmaceutical company focused on late-stage women’s health products, convened the inaugural meeting of its Oncology Steering Committee July 14th in New York City. The group, which included world-renowned experts focused on the prevention, diagnosis and treatment of breast cancer, [...]
Read more

NY Times Opinion Pages: Women’s Wariness of the Risks of Osteoporosis Drugs

  From the June 15th, 2016 New York Times: As a practicing obstetrician-gynecologist for 20 years, I saw firsthand how fear could be a very real factor in patient decision-making. Bisphosphonates are drugs that reduce osteoporotic fractures by suppressing bone turnover at a higher rate than normal. In rare cases, overpowering this natural remodeling process […]
Read more